The "Age of Blood Evaluation" Trial The "Age of Blood Evaluation" (ABLE) tested the hypothesis that the transfusion of prestorage leukoreduced RBCs stored for 7 days or less (fresh arm) as compared with standard-issue RBCs stored, on average, 18 to 21 days (control arm) will lead to improved clinical outcomes in the intensive care population. Prof. Lacroix began this study in 2009 in Canada and it extended to the UK, France and the Netherlands. Prof. Walsh was the Chief Investigator in the UK where twenty Intensive Care Units were involved. The Scottish National Blood Transfusion Service, NHS Blood and Transplant and Northern Ireland Blood Transfusion Service provided support for this study. Image UK Chief Investigator: Prof. Timothy S. Walsh Number and location of participating sites (by region/ country): 18 UK sites NIHR CRN portfolio: 11299 ISR CTN: 44878718 Funder: NIHR Health Technology Assessment Board Start and End date of grant award: 1 September 2011 - 31 July 2016 Start and End date of recruitment: 16 January 2012 - 31 October 2016 Current Status: published. Link to New England Journal of Medicine article Contact Details: Sponsor - University of Edinburgh & NHS Lothian ACCORD Chief Investigator: Prof T, Walsh, Professor of Critical Care, Edinburgh University, Royal Infirmary of Edinburgh, 51 Little France Crescent, Edinburgh, EH16 4TJ Trial manager: Julia Boyd, Edinburgh Clinical Trials Unit, University of Edinburgh, Outpatients Building - 2nd Floor D36, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XU. : 0131 537 3842 or Julia.Boyd@ed.ac.uk ECTU involvement: Trial Management, Database (UKCRC) This article was published on 2024-09-24
